<DOC>
	<DOCNO>NCT00482508</DOCNO>
	<brief_summary>This study ass safety tolerability long-term treatment omalizumab plus current asthma therapy patient participate successfully complete treatment period study CIGE025IA04E1 . Patients participate CIGE025IA04E1 perceive patient investigator benefit receive treatment omalizumab plus current asthma therapy accord best medical practice</brief_summary>
	<brief_title>Safety Tolerability Omalizumab Poorly Controlled Moderate Severe Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Patients complete core study extension study CIGE24IA05E1 include visit 15 , without experience significant drugrelated adverse event Patients give write informed consent Patients receive study medication great 84 day since visit 15 study CIGE24IA05E1 Pregnant females nurse mother Patients know hypersensitivity ingredient Omalizumab relate drug Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2011</verification_date>
	<keyword>Asthma</keyword>
	<keyword>anti immunoglobulin E</keyword>
	<keyword>omalizumab</keyword>
</DOC>